Industry News

• U.S. to provide antiviral medication to Latin America and the Caribbean for H1N1 influenza  HHS Secretary Kathleen Sebelius announced that the United States will provide 420,000 treatment courses of Tamiflu (Oseltamavir) to the Pan-American Health Organization (PAHO) to fight the novel H1N1 influenza in Latin America and the Caribbean.
  Dept. of Health & Human Services July 02, 2009  
• Oncolytics Biotech completes patient enrolment in U.K. REOLYSIN(R) trial  Oncolytics Biotech announced that patient enrolment has been completed in the Phase II component of a Phase I/II U.K. trial of REOLYSIN combined with paclitaxel/carboplatin for patients with advanced cancers.
  Oncolytics Biotech Inc. July 02, 2009  
• Phase III study showed Lucentis improved vision in branch retinal vein occlusion  Genentech announced that the Phase III study BRAVO showed Lucentis(R) (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in patients with macular edema due to branch retinal vein occlusion.
  Genentech Inc. July 02, 2009  
• FDA approves Multaq to treat heart rhythm disorder  The U.S. Food and Drug Administration has approved Multaq tablets (dronedarone) to help maintain normal heart rhythms in patients with a history of atrial fibrillation or atrial flutter (heart rhythm disorders).
  FDA July 02, 2009  
• Johnson & Johnson and Elan Corporation announce definitive agreement  Johnson & Johnson and Elan Corporation announced a definitive agreement whereby Johnson & Johnson will acquire substantially all of the assets and rights of Elan related to its Alzheimer's Immunotherapy Program (AIP Program), through a newly formed company.
  Johnson & Johnson July 02, 2009  
• Illumina launches multi-sample indexing for GoldenGate(R) Assay  Illumina launched GoldenGate Indexing, a high-throughput genotyping solution that utilizes multi-sample indexing technology. Researchers may now screen up to 16 times as many samples per reaction as the standard GoldenGate Assay.
  Illumina, Inc. July 02, 2009  
• Theravance announces new employment inducement awards  Theravance reported that equity awards were made to three new employees. Pursuant to Nasdaq Marketplace Rule 4350(i)(1)(A)(iv), the equity awards were granted under the Theravance 2008 New Employee Equity Incentive Plan.
  Theravance, Inc. July 01, 2009  
• Graceway Pharmaceuticals acquires early-stage dermatological molecules from Pfizer  Graceway Pharmaceuticals and Pfizer announced that they have entered into an Acquisition and License Agreement by which Graceway will acquire worldwide commercial rights for three investigational dermatological molecules from Pfizer and the related transferred or licensed intellectual properties.
  Pfizer Inc. July 01, 2009  
• Illumina announces preliminary revenue for second quarter 2009  Illumina announced, based on management's preliminary financial review, second quarter revenue of approximately $161 million compared to guidance of $168 to $173 million.
  Illumina, Inc. July 01, 2009  
• FDA: Boxed warning on serious mental health events to be required for Chantix and Zyban  The U.S. Food and Drug Administration announced that it is requiring manufacturers to put a Boxed Warning on the prescribing information for the smoking cessation drugs Chantix (varenicline) and Zyban (bupropion).
  FDA July 01, 2009  

   (next 10 articles)